1
|
Wang C, Zhang Q, Yu L, Chen L, Chen J. Abrocitinib for prurigo nodularis: Clinical efficacy and safety profile. J Eur Acad Dermatol Venereol 2024. [PMID: 39264711 DOI: 10.1111/jdv.20322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2024] [Accepted: 08/16/2024] [Indexed: 09/13/2024]
Affiliation(s)
- Changchun Wang
- Department of Dermatology, Wuhan No. 1 Hospital, Wuhan, China
- Department of Dermatology, Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Quanhong Zhang
- Department of Dermatology, Wuhan No. 1 Hospital, Wuhan, China
- Department of Dermatology, Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Lang Yu
- Department of Dermatology, Wuhan No. 1 Hospital, Wuhan, China
- Jianghan University School of Medicine, Wuhan, China
| | - Liuqing Chen
- Department of Dermatology, Wuhan No. 1 Hospital, Wuhan, China
- Hubei Province & Key Laboratory of Skin Infection and Immunity, Wuhan, China
| | - Jinbo Chen
- Department of Dermatology, Wuhan No. 1 Hospital, Wuhan, China
- Hubei Province & Key Laboratory of Skin Infection and Immunity, Wuhan, China
| |
Collapse
|
2
|
Lee J, Kim Y, Shin K, Kim HS, Ko HC, Kim MB, Kim BS. Treatment With Upadacitinib in Refractory Prurigo Nodularis: A Prospective Cohort Study. ALLERGY, ASTHMA & IMMUNOLOGY RESEARCH 2024; 16:546-554. [PMID: 39363772 PMCID: PMC11450437 DOI: 10.4168/aair.2024.16.5.546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/01/2024] [Revised: 05/12/2024] [Accepted: 06/11/2024] [Indexed: 10/05/2024]
Abstract
Prurigo nodularis (PN) is a chronic neuroinflammatory dermatosis with severe pruritus that has limited efficacy in various conventional treatments. This study investigated the outcomes of upadacitinib treatment in patients with refractory PN. A prospective study was conducted to screen for potential chronic infections prior to treatment. Upadacitinib was administered at a daily dose of 15 mg for 24 weeks, and the treatment response was assessed using the itch Numeric Rating Scale (NRS), investigator's Global Assessment (IGA), and Dermatology Life Quality Index (DLQI). Adverse events were monitored at each visit. Ten patients, with an average age of 48.8 years, were included in the study. All participants were treated with systemic cyclosporine before receiving upadacitinib, which yielded limited responses. At baseline, the mean prurigo severity scores assessed using the IGA, DLQI, and itch NRS were 3.4, 17.8, and 8.1, respectively; after 24 weeks of treatment, these scores significantly reduced to 1.0, 0.6, and 0.8, respectively. No severe adverse effects were observed. In conclusion, upadacitinib could be considered an alternative therapeutic option with good tolerability for refractory PN.
Collapse
Affiliation(s)
- Jungsoo Lee
- Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, Korea
- Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea
| | - Youngbeom Kim
- Department of Dermatology, College of Medicine, Pusan National University, Busan, Korea
- Biomedical Research Institute, Pusan National University Hospital, Busan, Korea
| | - Kihyuk Shin
- Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, Korea
- Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea
| | - Hoon-Soo Kim
- Department of Dermatology, College of Medicine, Pusan National University, Busan, Korea
- Biomedical Research Institute, Pusan National University Hospital, Busan, Korea
| | - Hyun-Chang Ko
- Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, Korea
- Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea
- Department of Dermatology, College of Medicine, Pusan National University, Busan, Korea
| | - Moon-Bum Kim
- Department of Dermatology, College of Medicine, Pusan National University, Busan, Korea
- Biomedical Research Institute, Pusan National University Hospital, Busan, Korea
| | - Byung-Soo Kim
- Department of Dermatology, College of Medicine, Pusan National University, Busan, Korea
- Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
| |
Collapse
|
3
|
Pezzolo E, Narcisi A, Gargiulo L, Di Lernia V, Napolitano M, Patruno C, Ribero S, Ortoncelli M, Foti C, Romita P, Gurioli C, Schena D, Ferrucci SM, Barei F, Amoruso GF, Russo F, Naldi L. Effective response to upadacitinib in patients affected by prurigo nodularis and by atopic dermatitis with a predominant prurigo nodularis pattern: A multicenter case series study. J Am Acad Dermatol 2024:S0190-9622(24)02538-6. [PMID: 39047985 DOI: 10.1016/j.jaad.2024.06.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2024] [Revised: 06/02/2024] [Accepted: 06/24/2024] [Indexed: 07/27/2024]
Affiliation(s)
- Elena Pezzolo
- Department of Dermatology, San Bortolo Hospital, Vicenza, Italy; A Study Centre of the Italian Group for the Epidemiologic Research in Dermatology (GISED), Bergamo, Italy.
| | - Alessandra Narcisi
- Dermatology Unit, Scientific Institute for Research, Hospitalization and Healthcare Humanitas Research Hospital, Milan, Italy
| | - Luigi Gargiulo
- Dermatology Unit, Scientific Institute for Research, Hospitalization and Healthcare Humanitas Research Hospital, Milan, Italy
| | - Vito Di Lernia
- Department of Dermatology, Arcispedale S. Maria Nuova, Azienda USL-Scientific Institute for Research, Hospitalization and Healthcare di Reggio Emilia, Reggio Emilia, Italy
| | - Maddalena Napolitano
- Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - Cataldo Patruno
- Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy
| | - Simone Ribero
- Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Michela Ortoncelli
- Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Caterina Foti
- Department of Precision and Regenerative Medicine and Ionian Area, Unit of Dermatology, University of Bari Aldo Moro, Bari, Italy
| | - Paolo Romita
- Department of Precision and Regenerative Medicine and Ionian Area, Unit of Dermatology, University of Bari Aldo Moro, Bari, Italy
| | - Carlotta Gurioli
- Department of Dermatology, Scientific Institute for Research, Hospitalization and Healthcare Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy
| | - Donatella Schena
- Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy
| | - Silvia Mariel Ferrucci
- Department of Dermatology, Fondazione Scientific Institute for Research, Hospitalization and Healthcare Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Francesca Barei
- Department of Dermatology, Fondazione Scientific Institute for Research, Hospitalization and Healthcare Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | | | - Filomena Russo
- Department of Dermatology, Istituto Dermopatico dell'Immacolata Scientific Institute for Research, Hospitalization and Healthcare, Rome, Italy
| | - Luigi Naldi
- Department of Dermatology, San Bortolo Hospital, Vicenza, Italy; A Study Centre of the Italian Group for the Epidemiologic Research in Dermatology (GISED), Bergamo, Italy
| |
Collapse
|
4
|
Lou F, Wang Y, Xiao Y, Liu Y. Upadacitinib for moderate to severe atopic dermatitis with generalized prurigo nodularis. Asian J Surg 2024; 47:3084-3088. [PMID: 38448287 DOI: 10.1016/j.asjsur.2024.02.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2024] [Accepted: 02/22/2024] [Indexed: 03/08/2024] Open
Affiliation(s)
- Fanglu Lou
- Department of Dermatology, The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine, Chongqing, 400011, PR China; Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine, No. 40 Daomenkou St., District Yuzhong, Chongqing, 400011, PR China; Chongqing Key Laboratory of Integrative Dermatology Research, Chongqing, PR China; Chongqing Clinical Research Center for Dermatology, Chongqing, PR China
| | - Yuyi Wang
- Department of Dermatology, The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine, Chongqing, 400011, PR China; Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine, No. 40 Daomenkou St., District Yuzhong, Chongqing, 400011, PR China; Chongqing Key Laboratory of Integrative Dermatology Research, Chongqing, PR China; Chongqing Clinical Research Center for Dermatology, Chongqing, PR China
| | - Yujuan Xiao
- Department of Dermatology, The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine, Chongqing, 400011, PR China; Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine, No. 40 Daomenkou St., District Yuzhong, Chongqing, 400011, PR China; Chongqing Key Laboratory of Integrative Dermatology Research, Chongqing, PR China; Chongqing Clinical Research Center for Dermatology, Chongqing, PR China.
| | - Yi Liu
- Department of Dermatology, The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine, Chongqing, 400011, PR China; Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine, No. 40 Daomenkou St., District Yuzhong, Chongqing, 400011, PR China; Chongqing Key Laboratory of Integrative Dermatology Research, Chongqing, PR China; Chongqing Clinical Research Center for Dermatology, Chongqing, PR China.
| |
Collapse
|
5
|
Ding W, Wang Y, Song L, Zhou N. A potential new treatment with upadacitinib for acquired reactive perforating collagenosis. JAAD Case Rep 2024; 48:112-114. [PMID: 38813063 PMCID: PMC11134568 DOI: 10.1016/j.jdcr.2024.04.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2024] Open
Affiliation(s)
- Wei Ding
- Department of Dermatology, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
| | - Yuting Wang
- Department of Dermatology, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
| | - Linyi Song
- Department of Dermatology, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
| | - Naihui Zhou
- Department of Dermatology, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
| |
Collapse
|
6
|
Shao Y, Wang D, Zhu Y, Xiao Z, Jin T, Peng L, Shen Y, Tang H. Molecular mechanisms of pruritus in prurigo nodularis. Front Immunol 2023; 14:1301817. [PMID: 38077377 PMCID: PMC10701428 DOI: 10.3389/fimmu.2023.1301817] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2023] [Accepted: 11/13/2023] [Indexed: 12/18/2023] Open
Abstract
Pruritus is the most common symptom of dermatological disorders, and prurigo nodularis (PN) is notorious for intractable and severe itching. Conventional treatments often yield disappointing outcomes, significantly affecting patients' quality of life and psychological well-being. The pathogenesis of PN is associated with a self-sustained "itch-scratch" vicious cycle. Recent investigations of PN-related itch have partially revealed the intricate interactions within the cutaneous neuroimmune network; however, the underlying mechanism remains undetermined. Itch mediators play a key role in pruritus amplification in PN and understanding their action mechanism will undoubtedly lead to the development of novel targeted antipruritic agents. In this review, we describe a series of pruritogens and receptors involved in mediating itching in PN, including cytokines, neuropeptides, extracellular matrix proteins, vasculogenic substances, ion channels, and intracellular signaling pathways. Moreover, we provide a prospective outlook on potential therapies based on existing findings.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Hui Tang
- Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China
| |
Collapse
|